---
title: The pharmaceutical industrys structure and economics
videoId: EixhVBV2yzo
---

From: [[acquiredfm]] <br/> 

The pharmaceutical industry, often considered the most complex industry to study, has undergone significant transformations over the last century, evolving from a simpler time before regulatory bodies like the Food and Drug Administration (FDA) and widespread industry consolidation <a class="yt-timestamp" data-t="00:03:40">[00:03:40]</a>. This industry is characterized by high risk, high potential returns, and unique market dynamics <a class="yt-timestamp" data-t="03:11:46">[03:11:46]</a>.

## Historical Context and Early Market Dynamics

Before the widespread use of antibiotics and vaccines, the medical landscape was very different, with a prevalence of "snake oil salesman" patent medicines <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>. A major breakthrough occurred in 1921 with the discovery and extraction of insulin in Toronto, Canada <a class="yt-timestamp" data-t="00:05:31">[00:05:31]</a>. Insulin, a pancreatic hormone, regulates glucose absorption and its insufficiency leads to diabetes <a class="yt-timestamp" data-t="00:05:46">[00:05:46]</a>. At the time, type 1 diabetes was a death sentence, leading to starvation diets as the primary treatment <a class="yt-timestamp" data-t="00:07:17">[00:07:17]</a>.

The discovery of insulin was groundbreaking, earning the 1923 Nobel Prize in Physiology or Medicine <a class="yt-timestamp" data-t="00:08:29">[00:08:29]</a>. However, the early extraction methods from dog pancreases were not scalable <a class="yt-timestamp" data-t="00:10:40">[00:10:40]</a>. A significant ethical and commercial challenge arose as it was perceived as unethical to profit from medical breakthroughs <a class="yt-timestamp" data-t="00:12:20">[00:12:20]</a>. The University of Toronto licensed production rights to Eli Lilly, an American company, which found an abundant source in cow and pig pancreases from slaughterhouses <a class="yt-timestamp" data-t="00:14:15">[00:14:15]</a>. This arrangement was initially a one-year exclusive development license, requiring Eli Lilly to report back any manufacturing advances to the University of Toronto, but allowing them to retain brand ownership <a class="yt-timestamp" data-t="00:15:20">[00:15:20]</a>.

At the same time, Danish scientists, including Nobel laureate August Krogh and physician Hans Christian Hagedorn, began their own insulin production in Copenhagen in 1922-1923, leading to the founding of Nordisk Insulin <a class="yt-timestamp" data-t="00:24:30">[00:24:30]</a>. Intense local competition soon emerged with the founding of Novo Insulin by former Nordisk employees, who developed shelf-stable liquid insulin and sold it at half the price <a class="yt-timestamp" data-t="00:40:40">[00:40:40]</a>. This fierce rivalry drove significant innovation in insulin formulations and delivery systems for over 65 years <a class="yt-timestamp" data-t="00:41:21">[00:41:21]</a>.

## Market Growth and Technological Revolutions

The market for insulin and diabetes treatment became "a bigger market to go after" <a class="yt-timestamp" data-t="00:12:12">[00:12:12]</a> due to the chronic nature of the disease, requiring lifelong daily injections <a class="yt-timestamp" data-t="00:42:43">[00:42:43]</a>. This created a consistent, long-term revenue stream for pharmaceutical companies <a class="yt-timestamp" data-t="00:43:08">[00:43:08]</a>.

A major shift in the [[insulin_market_and_pricing_dynamics | Insulin market and pricing dynamics]] occurred in the 1980s with the advent of recombinant DNA and genetic engineering, pioneered by Genentech and Eli Lilly <a class="yt-timestamp" data-t="01:14:46">[01:14:46]</a>. This technology allowed for the production of human insulin, eliminating reliance on animal pancreases <a class="yt-timestamp" data-t="01:15:27">[01:15:27]</a>. While not necessarily more efficacious, it offered a significant manufacturing and scale advantage <a class="yt-timestamp" data-t="01:16:06">[01:16:06]</a>. The number of type 2 diabetes patients quadrupled between 1980 and 2016 <a class="yt-timestamp" data-t="01:13:40">[01:13:40]</a>. This explosion in patient population, coupled with genetic engineering, transformed the global insulin market from roughly \$500 million in 1980 to over \$2 billion by 1989 <a class="yt-timestamp" data-t="01:33:46">[01:33:46]</a>.

## Industry Consolidation and the Healthcare Value Chain

The late 1980s and early 1990s saw massive consolidation in the pharmaceutical industry, with mergers like Glaxo and Wellcome, and Astra and Zeneca <a class="yt-timestamp" data-t="01:34:46">[01:34:46]</a>. Scale became increasingly important for R&D, trials, approvals, and market negotiation <a class="yt-timestamp" data-t="01:21:46">[01:21:46]</a>.

The U.S. healthcare value chain is notoriously complex:
*   **Manufacturers** (like Novo Nordisk) develop and produce drugs, also owning clinical trials <a class="yt-timestamp" data-t="01:26:00">[01:26:00]</a>.
*   **Distributors/Wholesalers** (e.g., McKesson, Cardinal Health) buy drugs from manufacturers, warehouse them, and distribute to pharmacies, taking on inventory risk <a class="yt-timestamp" data-t="01:26:13">[01:26:13]</a>.
*   **Pharmacies** sell drugs to customers <a class="yt-timestamp" data-t="01:26:27">[01:26:27]</a>.
*   **Insurance Companies** typically pay for drugs, but outsource price negotiation <a class="yt-timestamp" data-t="01:24:17">[01:24:17]</a>.
*   **Pharmacy Benefits Managers (PBMs)** negotiate discounts (often rebates) with Pharma companies on behalf of insurance companies <a class="yt-timestamp" data-t="01:24:33">[01:24:33]</a>. PBMs manage pharmacy benefits for 266 million Americans and are highly concentrated, with three major players covering about 80% of the market <a class="yt-timestamp" data-t="01:28:12">[01:28:12]</a>.
*   **Employers** are also involved, often sharing discounts from healthcare plans <a class="yt-timestamp" data-t="01:24:55">[01:24:55]</a>.

This multi-intermediary system makes it "really hard to have a functioning market" and obscures demand signals from the end consumer <a class="yt-timestamp" data-t="01:25:31">[01:25:31]</a>. Rebates can be extremely high; Eli Lily claimed that discounts and rebates accounted for 75% of the sticker price of insulin <a class="yt-timestamp" data-t="01:30:34">[01:30:34]</a>. These rebates are generally passed along to the healthcare plan, not directly to the patient <a class="yt-timestamp" data-t="01:30:55">[01:30:55]</a>.

## Business Strategies and Pricing in Pharma

[[business_strategies_and_pricing | Business Strategies and Pricing]] in pharma are heavily influenced by the product type and market. Historically, insulin manufacturers faced a balancing act between humanitarian access and commercial viability, with some companies like Nordisk initially mandated to sell at cost in their home region and at market prices elsewhere to fund research <a class="yt-timestamp" data-t="00:35:47">[00:35:47]</a>.

The development of new drug classes, such as GLP-1 (glucagon-like peptide-1) agonists, highlights the industry's risk-reward profile. Early GLP-1 research faced industry abandonment due to the molecule's short half-life <a class="yt-timestamp" data-t="01:47:19">[01:47:19]</a>. However, persistent research led to longer-lasting analogs like liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy) <a class="yt-timestamp" data-t="01:48:49">[01:48:49]</a>.

### Weight Loss Drugs: A New Frontier
Weight loss drugs have a "dangerous history" and a persistent "stigma" against obesity as a disease <a class="yt-timestamp" data-t="02:00:32">[02:00:32]</a>. Prior to GLP-1s, the annual obesity drug market was tiny at \$744 million globally until 2020 <a class="yt-timestamp" data-t="02:03:10">[02:03:10]</a>. Researchers thought it was "impossible to create a weight loss drug that was both safe and effective" <a class="yt-timestamp" data-t="02:01:28">[02:01:28]</a>, due to past disasters like Fen-Phen, which caused major heart damage <a class="yt-timestamp" data-t="02:01:53">[02:01:53]</a>. The "magic number" for market viability is a drug that can safely enable someone to lose 10% or more of their body weight <a class="yt-timestamp" data-t="02:03:44">[02:03:44]</a>. Semaglutide's ability to achieve 15%+ long-term BMI reduction was a breakthrough <a class="yt-timestamp" data-t="02:16:03">[02:16:03]</a>.

The sticker price for Ozempic (diabetes) is over \$1,000/month in the US, and Wegovy (weight loss) is over \$1,300/month <a class="yt-timestamp" data-t="02:37:30">[02:37:30]</a>. In contrast, Ozempic costs \$147/month in Canada and \$93/month in the UK <a class="yt-timestamp" data-t="02:37:47">[02:37:47]</a>. This highlights a "uniquely American problem" <a class="yt-timestamp" data-t="02:37:55">[02:37:55]</a>.
Payers (insurers, employers, Medicare) are hesitant to cover these drugs due to the high short-term costs, especially given that 40% of the US population is obese <a class="yt-timestamp" data-t="02:34:06">[02:34:06]</a>. Medicare Part D is legally prohibited from paying for weight loss drugs <a class="yt-timestamp" data-t="02:30:53">[02:30:53]</a>, reflecting the societal bias that obesity is a lifestyle problem, not a disease <a class="yt-timestamp" data-t="02:31:14">[02:31:14]</a>.

## R&D and Profitability

The pharmaceutical industry is characterized by extremely high R&D costs. On average, it costs \$2.3 billion to bring a drug to market <a class="yt-timestamp" data-t="02:48:47">[02:48:47]</a>. The clinical trial process is lengthy and expensive:
*   Phase 1 (safety, dose finding): 9% of R&D spend <a class="yt-timestamp" data-t="01:56:36">[01:56:36]</a>
*   Phase 2 (preliminary efficacy): 12% of R&D spend <a class="yt-timestamp" data-t="01:56:40">[01:56:40]</a>
*   Phase 3 (confirm efficacy, robust safety data): 29% of R&D spend <a class="yt-timestamp" data-t="01:56:43">[01:56:43]</a>
Only 8% of drugs that enter preclinical studies make it through Phase 3 to regulatory approval <a class="yt-timestamp" data-t="01:58:07">[01:58:07]</a>. Most drugs, even after approval, "do not earn back their R&D costs" <a class="yt-timestamp" data-t="03:13:04">[03:13:04]</a>. The top 10% of drugs that make it to market provide 50% of the profits <a class="yt-timestamp" data-t="03:12:59">[03:12:59]</a>. This "power law" distribution means pharmaceutical companies need "Blockbuster" drugs (those achieving \$1 billion in annual revenue) to be successful <a class="yt-timestamp" data-t="03:13:36">[03:13:36]</a>.

While gross margins for successful drugs can be very high (e.g., Novo Nordisk at 84%, Eli Lily at 80%) <a class="yt-timestamp" data-t="02:24:28">[02:24:28]</a>, looking solely at these margins is misleading because they don't account for the massive R&D costs of failed drugs <a class="yt-timestamp" data-t="03:24:19">[03:24:19]</a>. Industry-wide Return on Invested Capital (ROIC) for pharma is around 13%, in line with other industries, though "the variance between companies has increased" <a class="yt-timestamp" data-t="03:25:55">[03:25:55]</a>.

## Industry "Powers" (Helmer's Seven Powers)

Applying Hamilton Helmer's "Seven Powers" framework, the pharmaceutical industry exhibits several key "powers" that allow companies to achieve persistent differential positive returns:

*   **Cornered Resource (Patents)**: This is a "patent driven industry" <a class="yt-timestamp" data-t="02:45:43">[02:45:43]</a>. Companies like Novo Nordisk hold patents on molecules like semaglutide until 2032 <a class="yt-timestamp" data-t="02:45:47">[02:45:47]</a>. Patents also extend to delivery mechanisms (e.g., insulin pens), providing additional defensibility <a class="yt-timestamp" data-t="02:47:27">[02:47:27]</a>.
*   **Scale Economies**: This applies on three fronts:
    *   **R&D**: High capital intensity (\$2.3 billion per drug on average) necessitates large scale to outrun fixed costs <a class="yt-timestamp" data-t="02:48:45">[02:48:45]</a>.
    *   **Production**: Manufacturing biologics (drugs from living cells) is complex and requires significant capital expenditure <a class="yt-timestamp" data-t="02:49:02">[02:49:02]</a>.
    *   **Go-to-Market**: Large sales forces and relationships with PBMs and distributors are crucial for broad market access <a class="yt-timestamp" data-t="02:49:07">[02:49:07]</a>.
*   **Switching Costs**: Once a patient finds a drug that works, they are unlikely to switch <a class="yt-timestamp" data-t="02:51:16">[02:51:16]</a>. For GLP-1s, the weight regain upon discontinuation creates a strong incentive to remain on the drug <a class="yt-timestamp" data-t="02:51:37">[02:51:37]</a>.
*   **Branding**: While less common historically, drugs like Ozempic have achieved significant Brand Power through widespread public awareness and media mentions, influencing consumer demand and doctor prescriptions <a class="yt-timestamp" data-t="02:49:26">[02:49:26]</a>.
*   **Network Effects**: For weight loss GLP-1s, a [[economics_of_network_effects | Network Effect]] is suggested through two mechanisms: a "tight feedback loop" (immediate noticeable weight loss) and users becoming "walking billboards" due to visible results, encouraging others to seek the drug <a class="yt-timestamp" data-t="02:51:50">[02:51:50]</a>. This creates a viral adoption dynamic unusual for pharma <a class="yt-timestamp" data-t="02:52:52">[02:52:52]</a>.

## Societal Judgments and Healthcare Costs

The US healthcare system is unique, consuming around 17-18% of GDP, up from 5% in 1960 <a class="yt-timestamp" data-t="03:14:16">[03:14:16]</a>. Despite this, life expectancy has declined in recent years, primarily due to non-healthcare related issues like mental health and overdoses <a class="yt-timestamp" data-t="03:16:26">[03:16:26]</a>.
A major criticism is the perceived over-earning by pharmaceutical companies. However, when considering the massive investments in R&D and the high failure rate of drugs, the returns for the industry as a whole are not exceptionally high compared to other sectors <a class="yt-timestamp" data-t="03:24:04">[03:24:04]</a>.

Conversely, the bulk of healthcare spending (87%) does not go to pharma <a class="yt-timestamp" data-t="03:27:08">[03:27:08]</a>. Hospitals account for 28% of revenue, and professional services (doctor's offices) 26% <a class="yt-timestamp" data-t="03:28:16">[03:28:16]</a>. Administrative costs of health insurance alone consume 8% of a "very very very large number" <a class="yt-timestamp" data-t="03:28:39">[03:28:39]</a>. While pharmaceutical companies take significant risk to innovate, health insurance companies generally maintain flat or growing profits, even during crises like COVID, suggesting they operate more as "access" providers than true insurers that bear significant risk <a class="yt-timestamp" data-t="03:29:57">[03:29:57]</a>.

The healthcare system designed for acute and infectious diseases is now struggling with chronic illnesses, which require a different approach to treatment, regulation, and payment <a class="yt-timestamp" data-t="03:19:57">[03:19:57]</a>.